Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.256 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection among infants and young children. Since October 2021, the Advisory Committee on Immunization Practices (ACIP) Maternal and Pediatric RSV Work Group has reviewed evidence on the safety and efficacy of nirsevimab among infants and young children. On August 3, 2023, ACIP recommended nirsevimab for all infants aged <8 months who are born during or entering their first RSV season and for infants and children aged 8-19 months who are at increased risk for severe RSV disease and are entering their second RSV season. On the basis of pre-COVID-19 pandemic patterns, nirsevimab could be administered in most of the continental United States from October through the end of March. Nirsevimab can prevent severe RSV disease among infants and young children at increased risk for severe RSV disease.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- MMWR Morbidity and Mortality Weekly Report
- Topic
- Respiratory viral infections research
- Field
- Medicine
- Canadian institutions
- —
- Funders
- National Institute of Allergy and Infectious DiseasesPediatric Infectious Diseases SocietyOffice of the Assistant Secretary for HealthHealth Resources and Services AdministrationCollege of Medicine, Drexel UniversityCenters for Disease Control and PreventionPublic Health AgencyMcGovern Medical SchoolVanderbilt University Medical CenterPublic Health Agency of CanadaWake Forest School of MedicineWestern Michigan UniversityDartmouth CollegeResearch Institute, Nationwide Children's HospitalSchool of Medicine, Stanford UniversityVanderbilt UniversityDrexel UniversityNationwide Children's HospitalUniversity of WashingtonStrongKaiser PermanenteEmory UniversityBrown UniversityMinnesota Department of HealthWorld Health OrganizationU.S. Department of Health and Human Services
- Keywords
- MedicineAdvisory committeePalivizumabPediatricsImmunizationDiseaseRespiratory tract infectionsLower respiratory tract infectionPandemicVirusRespiratory systemImmunologyInfectious disease (medical specialty)Coronavirus disease 2019 (COVID-19)AntibodyInternal medicine
- Has abstract in OpenAlex
- yes